ValuEngine upgraded shares of Vaccinex (NASDAQ:VCNX) from a hold rating to a buy rating in a research report released on Thursday morning, ValuEngine reports.

Separately, Zacks Investment Research reissued a hold rating on shares of Vaccinex in a research report on Saturday, October 19th.

Shares of VCNX traded up $0.03 during mid-day trading on Thursday, reaching $5.09. The company’s stock had a trading volume of 4,100 shares, compared to its average volume of 4,575. Vaccinex has a 12-month low of $3.77 and a 12-month high of $8.49. The stock has a market cap of $75.65 million, a PE ratio of -0.98 and a beta of 1.50. The company’s 50 day moving average is $5.15 and its 200 day moving average is $5.35.

Vaccinex (NASDAQ:VCNX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.10. The firm had revenue of $0.40 million during the quarter. Vaccinex had a negative return on equity of 585.69% and a negative net margin of 4,740.03%. Sell-side analysts forecast that Vaccinex will post -2.57 EPS for the current fiscal year.

A hedge fund recently raised its stake in Vaccinex stock. Oppenheimer & Co. Inc. lifted its position in Vaccinex Inc (NASDAQ:VCNX) by 82.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,900 shares of the company’s stock after purchasing an additional 13,100 shares during the quarter. Oppenheimer & Co. Inc. owned approximately 0.19% of Vaccinex worth $207,000 at the end of the most recent quarter. Institutional investors own 10.04% of the company’s stock.

About Vaccinex

Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with's FREE daily email newsletter.